What is the purpose of this trial?
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Start Date: 02/06/2018
End Date: 12/31/2021
Last Updated: 02/22/2018
Study HIC#: 2000021969